oncolyt
virus
ov
virus
specif
result
kill
tumor
cell
repres
promis
class
cancer
therapi
recent
focu
ov
therapi
field
shift
direct
oncolyt
effect
immun
stimulatori
effect
ov
therapi
function
kick
start
antitumor
immun
respons
releas
tumor
associ
antigen
releas
inflammatori
signal
combin
ov
immun
modul
could
enhanc
efficaci
immun
ov
therapi
addit
genet
engin
ov
allow
local
express
immun
therapeut
therebi
reduc
relat
toxic
differ
option
modifi
tumor
microenviron
combin
ov
therapi
explor
possibl
obstacl
combin
discuss
review
vor
ramfouchi
erasmusmcnl
ram
fouchier
bvandenhoogen
erasmusmcnl
bg
van
den
hoogen
innat
adapt
immun
system
work
togeth
detect
transform
cell
remov
form
tumor
antitumor
respons
start
releas
tumor
associ
antigen
taa
die
cancer
cell
accompani
signal
molecul
attract
activ
cell
innat
immun
system
wherea
nk
cell
recogn
kill
tumor
cell
directli
antigen
present
cell
apc
dc
macrophag
take
taa
activ
adapt
immun
system
matur
apc
accompani
danger
signal
molecul
determin
skew
prefer
helper
cell
th
respons
signal
constitut
proinflammatori
cytokin
interleukin
il
type
interferon
ifn
tumor
necrosi
factor
tnf
damageassoci
molecular
pattern
molecul
damp
nuclear
protein
heatshock
protein
atp
cytokin
stimul
gener
tumor
specif
cytotox
cell
ctl
crucial
effector
cell
antitumor
respons
subsequ
effector
cell
includ
helper
cell
ctl
attract
tumor
site
via
gradient
cell
attract
chemokin
includ
chemokin
cc
motif
ligand
rant
chemokin
cxc
motif
ligand
site
ctl
recogn
kill
tumor
cell
mediat
mhcit
cell
receptor
interact
immun
system
succe
destruct
begin
tumor
host
remain
free
cancer
case
tumor
cell
reprogram
evad
immun
system
result
equilibrium
die
tumor
cell
tumor
cell
surviv
immun
attack
consequ
select
immunosuppress
less
immunogen
tumor
cell
variant
introduc
elimin
immun
system
tumor
cell
establish
tumor
microenviron
tme
function
antitumor
immun
cell
attenu
fig
first
tumor
cell
stromal
cell
endotheli
epitheli
cell
fibroblast
produc
factor
transform
growth
prostaglandin
disrupt
apc
matur
tme
result
dc
isol
tme
often
display
partli
matur
immun
suppress
phenotyp
secret
cytokin
induc
nonfavor
respons
secondli
tumor
inhibit
infiltr
effector
cell
repress
product
cell
attract
chemokin
modif
thirdli
effector
cell
infiltr
tumor
attenu
express
sever
immunosuppress
molecul
persist
exposur
tumor
antigen
result
helper
cell
ctl
isol
tme
often
present
exhaust
phenotyp
character
high
level
express
immun
checkpoint
receptor
cytotox
tlymphocyteassoci
protein
program
cell
death
protein
ligat
receptor
ligand
express
tumor
stromal
cell
also
immunosuppress
apc
lead
inhibit
tumor
specif
cell
respons
fourthli
regulatori
immun
cell
regulatori
cell
treg
myeloid
deriv
suppressor
cell
mdsc
recruit
tumor
site
similar
tumor
cell
treg
secret
indoleamin
ido
lead
attenu
cell
respons
furthermor
treg
consum
indispens
cell
activ
mdsc
contribut
suppress
effector
cell
product
arginas
nitric
oxid
depriv
cell
amino
acid
necessari
prolifer
despit
evas
mechan
ctl
helper
cell
still
consid
crucial
effector
cell
antitumor
immun
infiltr
tme
associ
good
prognosi
variou
type
cancer
proper
activ
cell
key
effect
antitumor
respons
abund
mechan
use
tumor
suppress
cell
offer
mani
target
cancer
immunotherapi
strategi
moment
multipl
strategi
target
tme
explor
recent
success
led
fda
approv
checkpoint
inhibitor
clinic
respons
treat
patient
clinic
respons
patient
treatment
melanoma
clinic
trial
shown
dual
synergist
blockag
improv
antitumor
respons
melanoma
indic
might
take
one
approach
induc
power
long
last
antitumor
immun
howev
system
administr
checkpoint
inhibitor
well
immunotherapi
often
coincid
sever
immunerel
advers
effect
similar
autoimmun
diseas
promis
treatment
option
potenti
overcom
obstacl
oncolyt
virotherapi
oncolyt
virotherapi
approach
use
oncolyt
virus
ov
either
natur
tropism
neoplast
cell
genet
modifi
enhanc
select
tumor
cell
tumor
cell
often
lack
adequ
antivir
respons
make
suscept
ov
infect
healthi
cell
viral
infect
lead
tumor
regress
two
distinct
mechan
direct
kill
tumor
cell
replic
depend
induc
cell
death
promot
antitumor
respons
toward
tumor
cell
includ
noninfect
cell
induc
immunogen
cell
death
type
immunogen
cell
death
immunogen
apoptosi
necrosi
autophag
cell
death
character
releas
taa
combin
damp
viral
pathogen
associ
molecular
pattern
pamp
follow
secret
damp
cytokin
innat
immun
cell
macrophag
dc
nk
cell
neutrophil
infiltr
tumor
environ
immun
stimul
cytokin
secret
lead
matur
apc
henc
present
taa
viral
antigen
activ
adapt
immun
system
lymph
node
cytotox
cell
start
infiltr
tumor
specif
elimin
cancer
cell
simultan
memori
cell
form
improv
protect
new
tumor
challeng
mous
model
therefor
evid
ov
therapi
function
kick
start
antitumor
immun
respons
provid
taa
immunogen
manner
induc
infiltr
immun
cell
recent
focu
oncolyt
virotherapi
field
shift
oncolyt
effect
immun
stimulatori
effect
recombin
ov
arm
immun
modul
enhanc
activ
immun
system
overcom
immunosuppress
tme
first
arm
ov
approv
fda
oncolyt
herpessimplexviru
hsv
express
gmcsf
show
improv
stromal
cell
pink
secret
immun
suppress
molecul
inhibit
matur
apc
matur
apc
migrat
lymph
node
activ
adapt
immun
system
b
result
activ
cell
migrat
tumor
driven
chemokin
gradient
howev
secret
chemokin
lower
tumor
result
reduc
cell
infiltr
c
cell
enter
tme
target
tumor
cell
inhibit
immun
suppress
receptor
express
tumor
stromal
cell
also
immun
suppress
apc
treg
mdsc
recruit
tme
secret
immun
suppress
molecul
inhibit
cell
respons
even
melanoma
treatment
cure
yet
tvec
therefor
mani
immun
modul
arm
ov
therapi
follow
obstacl
opportun
come
light
review
give
overview
stateoftheart
therapi
use
combin
immun
modul
treat
cancer
patient
give
hint
potenti
futur
direct
immun
therapi
treatment
cancer
aim
overcom
tumor
immun
suppress
environ
increas
antitumor
immun
immun
therapi
target
directli
indirectli
inhibitori
stimulatori
receptor
immun
cell
often
base
monoclon
antibodi
therapi
intend
restor
intratumor
balanc
cytokin
chemokin
favor
inflammatori
tme
attract
activ
immun
cell
interest
noncellular
therapi
combin
ov
therapi
solid
tumor
describ
cytokin
key
player
stimul
regul
antitumor
immun
respons
reason
one
first
immun
therapeut
approach
cancer
treatment
administr
recombin
cytokin
describ
essenti
cytokin
antitumor
respons
gmcsf
cytokin
stimul
differ
part
immun
system
gmcsf
recruit
apc
tme
normal
express
apc
stimul
polar
helper
cell
phenotyp
cell
growth
factor
improv
cell
expans
cytokin
promot
surviv
cell
also
play
import
role
nk
cell
activ
despit
plethora
immun
modulatori
action
cytokin
lost
popular
monotherapi
low
object
respons
rate
nonneglig
side
effect
upon
system
administr
one
promis
immun
therapeut
checkpoint
inhibitor
inhibitori
receptor
act
checkpoint
avoid
activ
express
cell
inhibit
cell
activ
lymph
node
surviv
tme
sever
checkpoint
inhibitor
approv
fda
first
treatment
inhibitor
result
reactiv
suppress
immun
cell
addit
block
lead
deplet
treg
combin
antibodi
antibodi
shown
increas
respons
treatment
advanc
melanoma
howev
frequenc
sever
immunerel
advers
event
also
enhanc
clinic
studi
monotherapi
group
vs
combin
therapi
group
anoth
disadvantag
therapi
fact
tumor
becom
resist
toward
checkpoint
inhibitor
result
varieti
coinhibitori
receptor
lymphocyt
activ
gene
cell
immunoglobulin
mucin
receptor
protein
recent
identifi
normal
activ
ligand
mhcii
apc
indirectli
reduc
cell
prolifer
interact
ligand
express
treg
induc
cell
death
cell
blockag
inhibitori
receptor
unleash
potent
antitumor
ctl
respons
clinic
preclin
develop
agonist
antibodi
also
develop
activ
costimulatori
receptor
express
cell
stimul
two
receptor
ligand
monoclon
antibodi
induc
activ
prolifer
surviv
cell
anoth
interest
target
express
dc
ligat
therapeut
antibodi
stimul
dc
matur
present
antigen
lead
effici
cell
prime
stimulatori
coreceptor
explor
today
gitr
might
benefit
effect
current
therapi
anoth
class
therapeut
constitut
dual
specif
recombin
antibodi
also
call
bispecif
cell
engag
bite
shown
promis
antitumor
therapeut
antibodi
simultan
bind
ctl
via
cell
receptor
tcr
tumor
antigen
express
tumor
cell
result
bypass
mhc
depend
antigen
present
exampl
therapi
blinatumomab
engag
ctl
tumor
cell
current
approv
fda
treat
acut
lymphoblast
leukemia
hematolog
malign
therapeut
treatment
solid
tumor
could
enhanc
combin
treatment
immun
ov
therapi
introduc
discuss
immun
stimul
checkpoint
inhibitor
cytokin
immun
modul
viral
vector
advers
event
reduc
resist
revert
treatment
respons
enhanc
sever
virus
engin
express
differ
cytokin
chemokin
cytokin
chemokin
attract
transgen
encod
small
gene
gener
easi
build
viral
genom
moreov
often
pleiotrop
effect
mean
target
differ
immun
cell
simultan
complet
overview
cytokin
chemokin
use
oncolyt
virotherapi
given
tabl
extens
studi
transgen
cytokin
gmcsf
gmcsf
promot
dc
recruit
matur
gmcsf
success
use
arm
hsv
arm
viru
approv
fda
name
tvec
treatment
metastat
melanoma
patient
besid
hsv
virus
also
arm
gmcsf
phase
clinic
trial
patient
colorect
hepatocellular
carcinoma
neuroblastoma
ewe
sarcoma
proven
efficaci
safeti
oncolyt
vaccinia
viru
vv
express
gmcsf
pexavec
addit
two
differ
adenoviru
serotyp
express
gmcsf
induc
long
term
surviv
patient
amongst
other
ovarian
colon
pancreat
breast
cancer
sever
side
effect
biopsi
obtain
patient
differ
metastat
tumor
show
increas
infiltr
tcell
macrophag
also
correl
patient
surviv
henc
addit
effect
gmcsf
vector
immun
modul
activ
promot
surviv
nk
cell
also
effector
cell
sever
virus
arm
test
differ
tumor
model
tabl
induc
tumor
infiltr
effector
cell
nk
cell
apc
neuroblastoma
glioma
mous
model
compar
hsvgmcsf
demonstr
effect
tumor
growth
inhibit
inject
tumor
well
metastas
squamou
cell
carcinoma
mous
model
prostat
cancer
mous
model
addit
mice
better
protect
tabl
combin
therapi
arm
oncolyt
virus
immun
modul
cytokin
gmcsf
hsv
adenocarcinoma
metastis
phase
breast
cancer
melanoma
phase
improv
peripher
blood
mononuclear
cell
respons
grade
adv
cell
infiltr
mv
longterm
immun
rechalleng
tumor
cell
vsv
ndv
adv
neuroblastoma
glioma
prostat
squamou
cell
carcinoma
melanoma
infiltr
macrophag
helper
ctl
nk
cell
sign
hsv
improv
surviv
protect
rechalleng
vsv
ndv
melanoma
hepatoma
squamou
cell
carcinoma
infiltr
helper
ctl
sign
hsv
immun
rechalleng
tumor
cell
vsv
colon
carcinoma
melanoma
increas
tumor
specif
ctl
blood
detect
tumor
ndv
n
filtrat
helper
ctl
iav
immun
rechalleng
tumor
cell
hsv
increas
surviv
mous
model
iav
mv
nonsmal
cell
lung
cancer
improv
surviv
mous
model
report
vv
mesothelioma
pancreat
adenocarcinoma
vsv
ndv
ndv
melanoma
mammari
colon
carcinoma
increas
cytokin
express
improv
dc
matur
report
vsv
increas
cell
infiltr
other
tnf
ndv
improv
cell
respons
report
vsv
adv
hsv
chemokin
vv
colon
carcinoma
improv
dc
matur
report
hsv
improv
infiltr
helper
cell
ctl
induc
respons
revert
respons
combin
dc
vaccin
costimulatori
ligand
hsv
neuroblastoma
melanoma
patient
immun
rechalleng
tumor
cell
low
grade
vv
sign
adv
decreas
infiltr
treg
mv
melanoma
infiltr
helper
ctl
sign
vv
decreas
infiltr
treg
myxv
improv
surviv
continu
next
page
jf
de
graaf
et
al
cytokin
growth
factor
review
challeng
tumor
cell
treat
group
indic
format
long
term
antitumor
respons
similarli
adenoviru
arm
show
improv
tumor
reduct
compar
adenoviru
arm
gmcsf
thyroid
cancer
rat
model
conclus
multipl
studi
demonstr
ov
arm
yield
better
antitumor
effect
vector
gmcsf
even
improv
combin
differ
immun
modul
signal
via
cytokin
receptor
common
chain
famili
import
stimul
prolifer
surviv
cell
nk
cell
system
treatment
associ
major
advers
side
effect
human
therefor
local
deliveri
ov
test
sever
research
group
murin
studi
reduc
tumor
growth
increas
cell
infiltr
tumor
report
distress
observ
mice
product
limit
tumor
site
might
indic
less
sideeffect
administr
human
also
mice
protect
rechalleng
tumor
cell
suggest
induct
long
term
tumor
specif
immun
thu
show
promis
vector
immun
modul
despit
promis
effect
show
sever
advantag
contrast
stimul
nk
effector
tcell
wherea
also
undesir
effect
stimul
treg
even
though
system
treatment
induc
less
toxic
effect
local
express
mediat
arm
vescilular
stomatitu
viru
vsv
enhanc
antitumor
activ
compar
vsv
treatment
combin
system
murin
model
vector
ndv
demonstr
induc
ctl
infiltr
increas
activ
tumorspecif
effector
cell
result
improv
surviv
rate
compar
melanoma
mous
model
altogeth
studi
indic
treatment
ov
express
effici
system
treatment
treatment
ov
express
import
antivir
respons
also
play
role
anticanc
immun
induc
dc
matur
ctl
nk
cell
activ
addit
result
upregul
mhc
express
tumor
cell
direct
effect
cell
prolifer
studi
investig
ov
arm
type
interferon
direct
antitumor
effect
express
measl
viru
mv
ndv
demonstr
immun
defici
mous
model
lead
improv
viral
therapi
buij
et
al
show
viru
express
interf
oncolyt
ndv
replic
wherea
willmon
et
al
li
et
al
found
viral
express
interfer
vsv
mv
replic
howev
immun
stimul
effect
viru
mediat
express
still
need
assess
immunocompet
model
determin
potenc
transgen
type
ii
interferon
import
effector
cytokin
secret
activ
cell
ctl
nk
cell
upregul
mhc
express
tumor
cell
promot
skew
via
autocrin
loop
recent
studi
describ
vsv
express
suggest
viru
induc
stronger
immun
respons
increas
mhc
antigen
present
tumor
cell
enhanc
dc
matur
attract
cell
tumor
site
induc
express
mice
author
observ
differ
viral
replic
even
though
also
known
antivir
activ
anoth
murin
studi
treatment
result
signific
benefici
effect
compar
unarm
ndv
conclus
arm
ov
shown
effect
efficaci
may
depend
viru
use
insuffici
infiltr
effector
lymphocyt
tumor
often
correl
low
efficaci
cell
stimul
immunotherapi
therefor
ov
arm
chemokin
attract
effector
cell
may
improv
antitumor
efficaci
addit
endogen
chemokin
releas
upon
viral
infect
import
chemokin
tme
rant
attract
cell
ctl
attract
undesir
treg
combin
ov
therapi
chemokin
modul
cocktail
induc
product
reduc
shown
promot
traffick
helper
cell
ctl
tme
result
improv
surviv
murin
colon
cancer
model
administr
virus
arm
result
increas
number
infiltr
cell
colon
cancer
neuroblastoma
conclus
studi
shown
use
ov
arm
chemokin
effici
increas
infiltr
cell
tumor
howev
none
studi
assess
infiltr
immun
cell
distant
tumor
tumor
reduct
mention
popular
immunotherapeut
checkpoint
inhibitor
yield
promis
effect
coincid
major
advers
effect
describ
addit
tumor
resist
immunotherapi
depend
immunogen
tumor
suppress
antitumor
immun
respons
tme
combin
system
immunotherapeut
local
ov
therapi
may
enhanc
therapeut
efficaci
may
overcom
tumor
resist
reduc
immun
relat
advers
effect
checkpoint
inhibitor
inhibit
earli
stage
cell
activ
lymph
node
also
stimul
undesir
treg
function
blockag
signal
releas
brake
cell
activ
even
deplet
intratumor
treg
intratumor
administr
ndv
combin
system
treatment
ipilimumab
show
improv
antitumor
effect
mediat
ctl
nk
cell
murin
melanoma
model
studi
use
combin
system
blockad
ov
vv
vsv
show
prolong
surviv
renal
lung
mammari
tumor
model
long
term
protect
rechalleng
tumor
cell
even
cure
mice
moreov
tvec
combin
system
blockad
evalu
therapi
melanoma
patient
yield
tumor
growth
control
significantli
greater
observ
monotherapi
incid
sever
advers
effect
similar
ipilimumab
monotherapi
local
express
induc
administr
adenoviru
arm
result
significantli
higher
concentr
antibodi
treat
tumor
plasma
level
remain
concentr
indic
safe
murin
model
howev
engeland
et
al
demonstr
treatment
mv
arm
less
effici
intratumor
treatment
mv
combin
system
administr
presum
major
site
action
lymph
node
peripheri
though
local
express
may
lead
transient
express
transgen
tumor
drain
lymph
node
studi
indic
system
therapi
may
requir
optim
respons
complet
differ
mechan
action
also
checkpoint
inhibitor
express
effector
cell
inhibit
cell
earli
activ
stage
lymph
node
signal
limit
function
activ
cell
later
stage
immun
respons
take
place
tumor
tissu
multipl
ov
mv
reoviru
vsv
combin
system
blockad
treatment
murin
glioblastoma
melanoma
acut
myeloid
leukemia
tumor
model
result
enhanc
influx
ctl
tumor
prolong
surviv
mice
specif
ctl
nk
cell
helper
cell
shown
mediat
benefici
effect
moreov
phase
clinic
trial
fda
approv
tvec
combin
result
good
respons
rate
patient
arm
myxoma
viru
myxv
result
improv
surviv
mice
well
howev
local
express
induc
administr
mv
vv
arm
demonstr
effici
therapi
unarm
vv
combin
system
treatment
murin
tumor
model
conclus
studi
suggest
ov
combin
checkpoint
inhibitor
improv
treatment
benefit
vector
differ
per
oncolyt
viru
express
apc
potent
costimulatori
molecul
cell
provid
costimul
via
interact
cell
inhibit
cell
interact
nevertheless
sever
ov
arm
test
pre
clinic
trial
treatment
melanoma
replic
defect
hsv
express
solubl
induc
prolong
tumor
specif
immun
respons
mice
bear
neuroblastoma
tumor
vv
express
eventu
evalu
melanoma
patient
treatment
well
toler
patient
respond
overal
ov
express
seem
addit
benefit
combin
transgen
singl
transgen
surfac
protein
primarili
present
activ
cell
nk
cell
signal
promot
skew
protect
cell
activ
induc
cell
death
enhanc
cytotox
activ
cell
nk
cell
signal
shown
potent
cell
activ
compar
costimul
combin
oncolyt
vv
system
administr
breast
cancer
model
result
increas
surviv
tumor
infiltr
ctl
compar
monotherapi
patient
surviv
vs
surviv
local
express
ligand
oncolyt
vv
mice
demonstr
enhanc
tumor
regress
effect
enhanc
even
combin
lymph
node
deplet
order
slow
viral
clearanc
local
inject
arm
viru
result
improv
ctltreg
ratio
tme
anoth
studi
vector
adenoviru
increas
helper
ctl
dc
infiltr
result
improv
surviv
mice
murin
model
dc
vaccin
combin
arm
adenoviru
combin
treatment
yield
even
better
result
dc
show
enhanc
migrat
tumor
drain
lymph
node
activ
cell
studi
shown
vector
immun
modul
ov
enhanc
therapeut
efficaci
matur
activ
statu
dc
often
limit
factor
induct
antitumor
immun
respons
ligat
receptor
provid
strong
activ
signal
dc
result
upregul
mhc
ii
costimulatori
molecul
product
import
skew
cell
toward
phenotyp
dc
activ
take
place
tme
treatment
ov
arm
stimulatori
antibodi
ligand
may
lead
enhanc
therapeut
efficaci
adenovirus
arm
test
melanoma
mous
model
patient
differ
type
cancer
treatment
express
vv
result
tumor
growth
inhibit
increas
infiltr
effector
cell
nk
cell
dc
melanoma
mous
model
howev
also
number
myeloid
deriv
suppressor
cell
increas
effect
unknown
evalu
clinic
trial
patient
show
diseas
control
month
system
tumor
specif
immun
respons
induc
similar
checkpoint
inhibitor
costimulatori
target
gitr
discov
antitumor
target
receptor
express
activ
cell
induc
product
cytokin
upon
interact
ligand
ligat
also
directli
blunt
suppress
effect
treg
arm
ov
describ
adenoviru
express
led
suppress
melanoma
lung
colon
tumor
growth
mice
effect
mediat
cell
ctl
increas
rather
cytokin
express
studi
combin
system
therapi
system
therapi
express
adenoviru
reveal
increas
express
cytokin
therebi
antitumor
ctl
respons
enhanc
lead
tumor
reject
colorect
cancer
model
involv
liver
metastas
compar
monotherapi
combin
arm
ov
treatment
make
interest
transgen
research
need
perform
elucid
benefici
effect
tumor
model
ov
gitr
stimulatori
receptor
express
activ
cell
also
constitut
express
treg
activ
receptor
promot
prolifer
cytokin
product
effector
cell
wherea
inhibit
treg
express
gitr
ligand
adenovir
vector
result
increas
infiltr
helper
cell
ctl
suppress
tumor
growth
lead
prolong
surviv
system
administr
stimul
gitr
antibodi
togeth
intratumor
inject
adenovir
vector
arm
result
enhanc
tumor
growth
inhibit
inject
distant
tumor
compar
singl
treatment
colon
pancreat
murin
cancer
model
make
gitr
ligand
attract
transgen
similar
research
need
perform
research
need
done
toward
target
like
newli
discov
light
antitumor
target
tabl
prostaglandin
princip
mediat
inflamm
express
tumor
cell
immun
cell
stimul
accumul
mdsc
tme
moreov
induc
ido
express
dc
wherea
reduc
express
necessari
induc
respons
recent
studi
reveal
import
mediat
resist
ov
therapi
immunotherapi
treatment
mice
vv
express
inactiv
enzym
name
hydroxyprostaglandin
dehydrogenas
hpgd
result
decreas
number
mdsc
tumor
yield
better
respons
block
agent
viru
also
shown
sensit
otherwis
resist
renal
tumor
treatment
thu
blockad
show
promis
result
approach
need
valid
tumor
model
ov
toll
like
receptor
tlr
part
innat
immun
system
recogn
pathogen
molecul
bacteri
lipid
protein
viral
dna
rna
type
tlr
activ
upon
infect
import
determin
skew
subsequ
adapt
immun
respons
manipul
tlr
signal
therefor
switch
induc
immun
respons
trif
mediat
signal
wherea
tlr
signal
via
moreov
pathway
induc
product
cytokin
instead
cytokin
manipul
signal
vv
engin
express
trif
increas
signal
addit
viral
particl
deglycosyl
result
reduc
respons
treatment
mice
deglycosyl
vvtrif
result
increas
product
cytokin
tme
also
viru
induc
infiltr
helper
cell
ctl
ctl
viru
tumor
cell
specif
vvtrif
show
improv
antitumor
efficaci
colon
renal
tumor
model
compar
vvgmcsf
pexavec
similar
result
obtain
use
intracellular
pattern
recognit
receptor
dnadepend
activ
ifnregulatori
factor
dai
vector
immun
modul
studi
show
antitumor
immun
respons
switch
manipul
intracellular
pathogen
receptor
signal
pathway
tumor
cell
bite
bispecif
cell
engag
class
bispecif
monoclon
antibodi
shown
promis
antitumor
effect
howev
short
halflif
therefor
requir
continu
infus
vaccinia
viru
vv
arm
bite
specif
tcr
taa
test
xenograft
lung
cancer
mous
model
studi
show
increas
tumor
cell
kill
cell
activ
skew
toward
respons
disadvantag
bite
target
one
taa
therefor
stimul
immun
respons
direct
taa
immunemodulatori
transgen
induc
immun
multipl
taa
releas
die
tumor
cell
improv
efficaci
ov
treatment
differ
combin
therapi
exploit
ov
arm
sever
cytokin
combin
test
promis
result
adenoviru
express
gmcsf
induc
infiltr
effector
cell
nk
cell
activ
apc
combin
dc
vaccin
melanoma
mous
model
well
longterm
protect
rechalleng
tumor
cell
moreov
viral
express
gmcsf
tme
shift
intratumor
cytokin
profil
prefer
respons
improv
dc
migrat
tumor
site
similarli
viral
coexpress
show
enhanc
therapeut
efficaci
increas
infiltr
dc
effector
cell
compar
monoexpress
murin
model
combin
show
synergist
effect
product
import
effector
cytokin
cell
nk
cell
polar
toward
respons
combin
express
import
tcell
chemokin
result
enhanc
neuroblastoma
growth
inhibit
compar
administr
arm
hsv
alon
demonstr
potenti
combin
differ
cytokin
chemokin
mice
addit
cytokin
also
combin
immun
stimulatori
receptor
ligand
treatment
adenoviru
arm
gmcsf
melanoma
mous
model
result
prolong
surviv
resist
tumor
rechalleng
compar
treatment
unarm
adenoviru
similarli
treatment
oncolyt
adenoviru
arm
well
result
often
complet
regress
melanoma
mous
model
compar
adenoviru
arm
alon
combin
three
arm
ov
yield
signific
better
result
inhibit
local
distant
tumor
growth
neuroblastoma
mous
model
compar
singl
vector
treatment
demonstr
possibl
synergist
effect
cytokin
costimulatori
receptor
combin
checkpoint
inhibitor
cytokin
work
equal
well
coadministr
oncolyt
adenoviru
express
gmcsf
oncolyt
adenoviru
express
shown
yield
addit
antitumor
activ
lung
cancer
mous
model
furthermor
tvec
combin
system
treatment
result
significantli
improv
tumor
growth
control
rate
patient
advanc
melanoma
compar
monotherapi
alon
current
tvec
combin
evalu
clinic
trial
result
still
unknown
addit
sorensen
et
al
engin
replic
defici
adenoviru
express
taa
combin
administr
viru
system
administr
stimulatori
antibodi
blockag
tumor
growth
melanoma
reduc
long
term
surviv
observ
mice
contrast
monotherapi
thu
stimul
dc
cell
necessari
long
term
antitumor
immun
respons
therefor
pre
clinic
trial
combinationtherapi
demonstr
potenti
improv
current
therapi
taken
togeth
studi
provid
strong
rational
evalu
ov
local
deliveri
vector
immunotherapi
target
costimulatori
coinhibitori
receptor
antitumor
effector
cell
part
tme
ov
repres
class
promis
agent
treat
cancer
besid
direct
oncolyt
effect
function
kickstart
antitumor
immun
combin
ov
therapi
exist
immun
therapi
enhanc
potenti
therapi
synerg
effect
mani
differ
combin
test
summar
review
tabl
studi
broaden
understand
strength
ov
immun
therapi
also
limit
result
learn
lesson
enabl
us
discuss
potenti
futur
direct
consider
decid
effect
immun
modul
viral
combin
reduc
risk
one
greatest
advantag
ov
arm
immun
modul
therapi
often
induc
safer
system
andor
effect
local
concentr
modul
system
monotherapi
nevertheless
vector
checkpoint
inhibitor
also
limit
potenc
immun
therapi
incorrect
local
time
resili
case
tumor
resist
regard
local
checkpoint
receptor
mainli
function
lymph
node
requir
system
deliveri
block
antibodi
instanc
arm
mv
prove
less
effect
monotherapi
inhibitor
similar
result
found
inhibitor
deliv
mv
vv
illustr
second
disadvantag
ov
arm
checkpoint
inhibitor
time
administr
combin
therapi
roja
et
al
gao
et
al
demonstr
system
administr
immun
therapeut
given
shortli
day
ov
therapi
result
addit
efficaci
combin
therapi
contrast
immun
therapeut
given
prior
ov
administr
howev
time
strategi
may
differ
per
viru
seen
arm
myxv
vector
result
addit
effect
addit
local
time
multipl
studi
shown
develop
resist
toward
checkpoint
inhibitor
time
new
inhibitori
molecul
upregul
cancer
cell
render
therapi
ineffect
system
administr
checkpoint
inhibitor
would
allow
easier
transit
checkpoint
therapi
necessari
therefor
think
arm
virus
checkpoint
inhibitor
might
effect
combin
strategi
altern
approach
consid
would
target
apc
nk
cell
ctl
arm
virus
immun
stimul
agonist
cytokin
immun
cell
express
known
stabl
subset
cytokin
costimulatori
receptor
henc
circumv
treatment
resist
seen
checkpoint
inhibitor
sever
studi
shown
addit
effect
ov
arm
agonist
agent
compar
ov
therapi
alon
tabl
addit
local
express
agonist
agent
reduc
advers
effect
contrast
system
administr
still
allow
combin
therapi
checkpoint
inhibitor
base
review
studi
reason
cytokin
agonist
target
costimulatori
receptor
promis
immun
modul
ov
treatment
solid
tumor
anoth
point
consider
combin
viru
immun
modul
viru
determin
kickstart
effect
initi
inflamm
concentr
durat
express
vector
immun
modul
howev
virus
differ
effect
kill
target
cell
express
immun
modul
exampl
studi
compar
vsv
replic
defect
adeno
viru
express
shown
replic
defect
viru
superior
increas
surviv
rate
replic
viru
probabl
low
immunogen
replic
defect
viru
result
reduc
viral
clearanc
immun
system
henc
immun
modul
secret
howev
whether
benefit
weaker
immun
respons
hold
true
therapi
remain
unknown
probabl
depend
viru
addit
oncolyt
activ
efficaci
ov
immun
therapi
influenc
effici
viru
express
immun
modul
instanc
ndv
shown
insert
site
viru
determin
express
level
transgen
effect
insert
site
may
also
hold
true
ov
often
discuss
addit
size
immun
modul
also
import
studi
use
complet
monoclon
antibodi
light
chain
singlechain
variabl
fragment
show
smaller
protein
effect
produc
larger
protein
cell
infect
vv
howev
singl
chain
fragment
without
igg
domain
degrad
faster
tme
result
similar
antitumor
activ
monoclon
antibodi
virus
toler
larg
insert
inform
consid
decid
modul
incorpor
howev
predict
effici
modul
express
remain
difficult
differ
express
level
occur
tumor
independ
viru
move
forward
ov
immun
therapi
clinic
safeti
ought
consid
far
advers
effect
report
therapi
combin
ov
immun
therapi
murin
model
clinic
trial
nevertheless
advers
effect
viral
infect
excess
viral
replic
express
immun
modul
lead
overreact
immun
system
exclud
yet
possibl
reduc
risk
advers
effect
would
incorpor
failsaf
mechan
ov
therapi
abort
viral
replic
necessari
hsv
drug
avail
inhibit
viral
replic
altern
viru
attenu
virul
virus
differ
host
rang
may
use
addit
incorpor
suicid
gene
thymidin
kinas
rat
cytochrom
cytosin
deaminas
would
allow
inhibit
viral
replic
use
drug
well
moreov
could
add
tumor
lytic
efficaci
therapi
ov
therapi
immun
modul
incorpor
host
genom
therefor
express
level
depend
viral
replic
usual
transient
thu
control
viral
replic
would
reduc
risk
sever
advers
effect
immun
modul
conclus
overal
effect
oncolyt
immun
therapi
depend
interplay
viru
immun
modul
tumor
tumor
develop
time
immun
system
well
mean
everi
stage
immun
activ
consid
decid
incorpor
immun
modul
fig
weak
immunogen
tumor
immunosuppress
tme
like
benefit
potent
oncolyt
virus
cytokin
innat
stimul
agonist
activ
initi
innat
immun
respons
eventu
tumor
inflam
effector
cell
nk
cell
respons
improv
immun
activ
agonist
checkpoint
inhibitor
vector
cytokin
immun
activ
agonist
could
reduc
possibl
advers
effect
compar
system
administr
wherea
system
deliveri
checkpoint
inhibitor
improv
time
local
treatment
futur
direct
explor
multipl
combin
dualli
arm
ov
allow
overcom
tumor
heterogen
least
use
ov
immun
modul
full
potenti
author
declar
conflict
interest
found
sponsor
role
design
studi
collect
analys
interpret
data
write
manuscript
decis
publish
result
work
support
sticht
technisch
wetenschappen
foundat
overleven
met
alvleesklierkank
wwwsupportcaspernl
tumor
cell
start
secret
viral
induc
cytokin
chemokin
also
immun
modul
improv
immun
activ
result
immun
cell
start
infiltr
tme
c
occasion
viru
induc
immunogen
cell
death
taa
immun
stimul
environ
result
matur
apc
apc
activ
adapt
immun
system
upon
cell
start
infiltr
tumor
attract
secret
chemokin
possibl
activ
immun
suppress
ligand
prevent
circul
immun
checkpoint
inhibitor
result
clearanc
tumor
ms
lisann
de
vor
receiv
master
degre
infect
immun
utrecht
netherland
follow
research
train
virosci
depart
erasmu
mc
rotterdam
netherland
karolinska
institut
swedensh
current
work
depart
microbiolog
utrecht
medic
institut
netherland
dr
bernadett
g
van
den
hoogen
start
research
train
group
prof
ross
pennsylvania
school
medicin
philadelphia
subsequ
bernadett
obtain
phd
depart
virosci
erasmu
mc
rotterdam
netherland
discoveri
character
human
metapneumoviru
hmpv
sinc
bernadett
investig
interact
hmpv
human
immun
system
use
paramyxovirus
oncolyt
virus
oncolyt
research
focus
avian
paramyxovirus
applic
oncolyt
viroimmunotherapi
treatment
pancreat
cancer
patient
